Dalmane Related Published Studies
Well-designed clinical trials related to Dalmane (Flurazepam)
A double-blind, placebo- and flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified release zolpidem in young healthy volunteers. [2006.06]
Effects of flurazepam and zolpidem on the perception of sleep in insomniacs. [1995.02]
Effects of estazolam and flurazepam on cardiopulmonary function in patients with chronic obstructive pulmonary disease. [1992.03]
Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the Multiple Sleep Latency Test. [1991.09]
Hypnotic efficacy of estazolam compared with flurazepam in outpatients with insomnia. [1991.08]
Differential side effect profile of triazolam versus flurazepam in elderly patients undergoing rehabilitation therapy. [1991.02]
Zopiclone versus flurazepam in insomnia: prolonged administration and withdrawal. [1990.10]
Cognitive performance and mood in patients with chronic insomnia during 14-day use of flurazepam and midazolam. [1990.08]
Sleep evaluation in chronic insomniacs during 14-day use of flurazepam and midazolam. [1990.08]
Clinical safety of flurazepam and midazolam during 14-day use in chronic insomniacs. [1990.08]
Sleep, performance, and plasma levels in chronic insomniacs during 14-day use of flurazepam and midazolam: methodology. [1990.08]
Sleep, performance, and plasma levels in chronic insomniacs during 14-day use of flurazepam and midazolam: an introduction. [1990.08]
Estazolam and flurazepam: a multicenter, placebo-controlled comparative study in outpatients with insomnia. [1990.05]
A comparison of the efficacy, tolerance and residual effects of zopiclone, flurazepam and placebo in insomniac outpatients. [1990.04]
A comparative study on the effects of brotizolam and flurazepam on sleep and performance in the elderly. [1989.08]
Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Flurazepam, temazepam, and triazolam. [1989.04]
Well-designed clinical trials possibly related to Dalmane (Flurazepam)
Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. [2006.01]
Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug. [2003.08]
Behavioral and hypnotic treatments for insomnia subtypes. [2003]
Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. [2000.01]
A dose-range finding study of zopiclone in insomniac patients. [1990.04]
Daytime sleepiness, performance, mood, nocturnal sleep: the effect of benzodiazepine and caffeine on their relationship. [1990.04]
The influence of age-dependent pharmacokinetics on the pharmacodynamics of hypnotic drugs: comparison of two hypnotics with different half-lives. [1989.03]
Other research related to Dalmane (Flurazepam)
Acute flurazepam intoxication: a case report. [2006.03]
Toxic epidermal necrolysis caused by flurazepam? [2005.12]
Flurazepam toxicosis in two dogs. [1997.12]
A fatality due to flurazepam. [1994.11]
Decreased expression of gamma-aminobutyric acid type A/benzodiazepine receptor beta subunit mRNAs in brain of flurazepam-tolerant rats. [1994.09]
Characterization of substantia nigra pars reticulata neurons based on response to iontophoretically applied GABA and flurazepam. [1993]
Behavioral tolerance to flurazepam. [1991.04]
Plasma concentrations of flurazepam and midazolam in chronic insomniacs during 14-day use and their relationship to therapeutic effects and next-day performance and mood. [1990.08]
Psychomotor performance in chronic insomniacs during 14-day use of flurazepam and midazolam. [1990.08]
Characteristics of chronic insomniacs examined in a multicenter 14-day study of flurazepam and midazolam. [1990.08]
Depot testosterone attenuates the anticonvulsant effect of flurazepam in mice. [1990]
Repeated dose effects of lormetazepam and flurazepam upon driving performance. [1990]
[Effects of flurazepam on disturbed sleep in patients with AIDS] [1989.12]
The effectiveness of flurazepam as night sedation prior to the removal of third molars. [1988.12]
Differential response to flurazepam in long-sleep and short-sleep mice. [1988.10]
Anaesthetic effects of flurazepam alone and in combination with thiopental or hexobarbital evaluated with an EEG-threshold method in male rats. [1988.03]
Comparison of lorazepam and flurazepam as hypnotic agents in chronic insomniacs. [1988.01]
Effects of flurazepam on sleep, arousal threshold, and the perception of being asleep. [1988]
Hepatic vs. gastrointestinal presystemic extraction of oral midazolam and flurazepam. [1987.12]
Effects of flurazepam and zopiclone on the performance of chronic insomniac patients: a study of ethanol-drug interaction. [1987]
Other possibly related research studies
H3 agonist immepip markedly reduces cortical histamine release, but only weakly promotes sleep in the rat. [2003.08]
Role of protein kinase A in GABAA receptor dysfunction in CA1 pyramidal cells following chronic benzodiazepine treatment. [2003.05]
Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent. [2001.07]
Effects of striatal injections of GABA(A) receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia. [2002.05.17]
Chronic benzodiazepine agonist treatment produces functional uncoupling of the gamma-aminobutyric acid-benzodiazepine receptor ionophore complex in cortical neurons. [1994.04]
Management of insomnia in office-based practice. National prevalence and therapeutic patterns. [1993.11]
Oral benzodiazepines and conscious sedation: a review. [1992.09]
Diagnosis and treatment of outpatient insomnia by psychiatric and nonpsychiatric physicians. [1992.07]
Insomnia in the elderly. [1992.06]
Clinical uses and advantages of low doses of benzodiazepine hypnotics. [1992.06]
Pharmacology of benzodiazepine hypnotics. [1992.06]
Chronic benzodiazepine treatment of rats induces reduction of paired-pulse inhibition in CA1 region of in vitro hippocampus. [1991.10.04]
A review of the safety profiles of benzodiazepine hypnotics. [1991.09]
The beneficial and adverse effects of hypnotics. [1991.07]
Avoiding the blanket approach to insomnia. Targeted therapy for specific causes. [1991.07]
Ultradian dynamics of sleep after a single dose of benzodiazepine hypnotics. [1991.03.19]
Propranolol does not alter flutoprazepam kinetics and metabolism in the rat. [1991.01]
Failure to limit quantities of benzodiazepine hypnotic drugs for outpatients: placing the elderly at risk. [1990.12]
Evaluation of experimental combined toxicity by use of dose-frequency curves: comparison with theoretical additivity as well as independence. [1990.10]
Effects of patient age and physician training on choice and dose of benzodiazepine hypnotic drugs. [1990.02]
Regional GABA/benzodiazepine receptor/chloride channel coupling after acute and chronic benzodiazepine treatment. [1989.08.11]
Rebound insomnia: a critical review. [1989.06]
Longitudinal study on pharmacodynamics and pharmacokinetics of acute, steady-state and withdrawn quazepam. [1989.02]
Delirium after elective orthopedic surgery: risk factors and natural history. [1989]
Modulation of GABA-gated chloride ion flux in rat brain by acute and chronic benzodiazepine administration. [1988.07]
Liquid chromatographic assay and pharmacokinetics of quazepam and its metabolites following sublingual administration of quazepam. [1988.06]
Chronic benzodiazepine treatment increases the effects of the inverse agonist FG7142. [1988.04]
Behavioral measurement of benzodiazepine tolerance and GABAergic subsensitivity in the substantia nigra pars reticulata. [1988.01.12]
Hypernatraemia and hyperchloraemic acidosis after bleach ingestion. [1988.01]
The use of benzodiazepine hypnotics in the elderly. [1988]
Hypothermia induced by baclofen, a possible index of GABAB receptor function in mice, is enhanced by antidepressant drugs and ECS. [1987.12]
Obtundation in the elderly patient: presentation of a drug overdose. [1987.11]
Bidirectional effects of chronic treatment with agonists and inverse agonists at the benzodiazepine receptor. [1987.09]
Sleep induction by an adrenal steroid in the rat. [1987]
Adverse reactions to benzodiazepine hypnotics: spontaneous reporting system. [1987]
Hypnotic residual effects of benzodiazepines with repeated administration. [1986.06]
A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. [2005.02]
Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial. [2004.08.01]
Transient plasticity of hippocampal CA1 neuron glutamate receptors contributes to benzodiazepine withdrawal-anxiety. [2004.11]
Residual effects of hypnotics: epidemiology and clinical implications. [2004]
The continuing challenge of inappropriate prescribing in the elderly: an update of the evidence. [2002.11]
Insomnia in children: when are hypnotics indicated? [2002]
The need for flexibility in dosing of hypnotic agents. [2000.02.01]
Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia. [2000.11]
[Acute lipoid pneumonia caused by accidental aspiration of vaseline used in nasogastric intubation] [2000.09]
Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. [2000.04]
A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience. [1999.12]
Rhabdomyolysis-induced acute renal failure after morphine overdose--a case report. [1999.09]
Management of insomnia. [1999.09]
High-dose discrimination training with midazolam: context determines generalization profile. [1999.10]
Anticonvulsant properties of 1,4-benzodiazepine derivatives in amygdaloid-kindled seizures and their chemical structure-related anticonvulsant action. [1998.11]
Psychotropic prescribing for the elderly in office-based practice. [1998.05]
Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. [1998.02]
The effects of fentanyl and sufentanil on cerebral hemodynamics. [1997.07]
Depression of early and late monosynaptic inhibitory postsynaptic potentials in hippocampal CA1 neurons following prolonged benzodiazepine administration: role of a reduction in Cl- driving force. [1997.02]
Solid-phase extraction and high-performance liquid chromatographic analysis of clozapine and norclozapine in human plasma. [1996.12]
Polysomnographic effects of hypnotic drugs. A review. [1996.07]
New evidence on benzodiazepine use and falls: the time factor. [1996.07]
|
